LATEST

• BUSINESS Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
  March 19, 2026

• BUSINESS Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
  March 19, 2026

• BUSINESS BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
  March 19, 2026

• BUSINESS Blenrep, Minjuvi, Zynyz, and More New Drugs Hit Japan Market
  March 19, 2026

• BUSINESS Celltrion, CMIC Forge Broad Partnership in Japan Biosimilars Business
  March 19, 2026

• BUSINESS J&J Launches Nurse-Led Support Program for Lung Cancer Patients in Japan
  March 19, 2026

• REGULATORY LDP Project Team Flags Drug Pricing as Key to Investment
  March 19, 2026

• BUSINESS Nipro’s Generic Radicut Gains ALS Nod, Aligning with Originator
  March 19, 2026

• BUSINESS Incyte Looks to More Than Double International Business by 2030: CEO
  March 18, 2026

• REGULATORY Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
  March 18, 2026

• REGULATORY MHLW Seeks Industry Survey on Petroleum-Linked Products amid Iran Crisis
  March 18, 2026

• BUSINESS Stella Pharma Files Steboronine for Recurrent Meningioma
  March 18, 2026

• REGULATORY MHLW Orders Label Revisions for Antiepileptics and Other Drugs
  March 18, 2026

• BUSINESS SymBio Enrolls First Patient in US for PIII BCV Trial in Adenovirus Infection
  March 18, 2026

• REGULATORY MHLW Panel OKs Draft Criteria for “Specified Medical Technologies”
  March 17, 2026

• REGULATORY Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
  March 17, 2026

• BUSINESS Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
  March 17, 2026

• BUSINESS ADDP, Proteros Tie Up to Expand Drug Discovery Support
  March 17, 2026

• BUSINESS Personal iPSC Service to Launch with Production Cost in the 10-Million-Yen Range
  March 17, 2026

• BUSINESS Olumiant Gains Oral Suspension Formulation in Japan
  March 17, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• Next ›
• 最終 »